Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Average Target Price of $93.14

Key Points

• Kiniksa Pharmaceuticals has a “Moderate Buy” consensus rating from nine analysts, with eight buys and one hold. The average 12-month price target is $93.14, above the reported share price of $79.48.
• The company reported quarterly revenue of $243.6 million, exceeding the $226.49 million analyst estimate, while earnings per share matched expectations at $0.30.
• Kiniksa shares have risen substantially, trading near their 52-week high of $82.98, while institutional investors own 53.95% of the stock and insiders own 51.98%.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $93.14.

A number of research firms recently commented on KNSA. Wall Street Zen cut Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 12th. Wedbush lifted their price target on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 29th. The Goldman Sachs Group upped their price objective on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. JPMorgan Chase & Co. upped their price objective on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Finally, Zacks Research lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, Director G. Bradley Cole sold 3,673 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director directly owned 11,672 shares in the company, valued at $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michael R. Megna sold 4,600 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the transaction, the chief accounting officer directly owned 29,062 shares in the company, valued at $2,333,678.60. This trade represents a 13.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 51.98% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its position in Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company's stock worth $35,436,000 after purchasing an additional 506,576 shares during the period. Rubric Capital Management LP boosted its position in Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company's stock valued at $180,562,000 after buying an additional 421,347 shares during the period. Janus Henderson Group PLC boosted its position in Kiniksa Pharmaceuticals International by 213.5% during the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company's stock valued at $23,197,000 after buying an additional 327,595 shares during the period. Spruce Street Capital LP boosted its position in Kiniksa Pharmaceuticals International by 75.0% during the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company's stock valued at $36,645,000 after buying an additional 326,081 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Kiniksa Pharmaceuticals International by 18.8% during the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company's stock valued at $39,086,000 after buying an additional 128,417 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $79.48 on Tuesday. The company's fifty day moving average price is $77.93 and its 200-day moving average price is $64.29. The firm has a market capitalization of $6.20 billion, a price-to-earnings ratio of 81.94 and a beta of 0.04. Kiniksa Pharmaceuticals International has a one year low of $35.20 and a one year high of $82.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The company had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. As a group, equities research analysts expect that Kiniksa Pharmaceuticals International will post 1.37 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.